NO2802345T3 - - Google Patents

Info

Publication number
NO2802345T3
NO2802345T3 NO12709369A NO12709369A NO2802345T3 NO 2802345 T3 NO2802345 T3 NO 2802345T3 NO 12709369 A NO12709369 A NO 12709369A NO 12709369 A NO12709369 A NO 12709369A NO 2802345 T3 NO2802345 T3 NO 2802345T3
Authority
NO
Norway
Application number
NO12709369A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2802345T3 publication Critical patent/NO2802345T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO12709369A 2012-01-12 2012-01-12 NO2802345T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (1)

Publication Number Publication Date
NO2802345T3 true NO2802345T3 (enExample) 2018-08-04

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12709369A NO2802345T3 (enExample) 2012-01-12 2012-01-12

Country Status (15)

Country Link
US (1) US9682042B2 (enExample)
EP (1) EP2802345B1 (enExample)
CN (1) CN104411326B (enExample)
AU (1) AU2012365465B2 (enExample)
BR (1) BR112014017217B1 (enExample)
CA (1) CA2861074C (enExample)
DK (1) DK2802345T3 (enExample)
ES (1) ES2670493T3 (enExample)
IN (1) IN2014MN01594A (enExample)
NO (1) NO2802345T3 (enExample)
PL (1) PL2802345T3 (enExample)
PT (1) PT2802345T (enExample)
RU (1) RU2602771C2 (enExample)
WO (1) WO2013104943A1 (enExample)
ZA (1) ZA201405107B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) * 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Also Published As

Publication number Publication date
CA2861074C (en) 2018-11-06
AU2012365465A1 (en) 2014-08-21
CA2861074A1 (en) 2013-07-18
EP2802345B1 (en) 2018-03-07
DK2802345T3 (en) 2018-04-30
ES2670493T3 (es) 2018-05-30
AU2012365465B2 (en) 2017-05-18
PL2802345T3 (pl) 2018-08-31
CN104411326B (zh) 2018-02-02
US20150132364A1 (en) 2015-05-14
PT2802345T (pt) 2018-04-24
EP2802345A1 (en) 2014-11-19
WO2013104943A1 (en) 2013-07-18
ZA201405107B (en) 2020-11-25
RU2014133042A (ru) 2016-02-27
RU2602771C2 (ru) 2016-11-20
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
US9682042B2 (en) 2017-06-20
CN104411326A (zh) 2015-03-11
IN2014MN01594A (enExample) 2015-05-08
BR112014017217A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
BR112014020090A2 (enExample)
BR112014019359A2 (enExample)
BR112014019144A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017607A2 (enExample)
BR112014017592A2 (enExample)
BR112014017646A2 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112013027865A2 (enExample)
BR112014017644A2 (enExample)
BR112014023495A2 (enExample)
BR112014017634A2 (enExample)
BR112014017647A2 (enExample)
BR112014013184A8 (enExample)
BR112014018625A2 (enExample)
BR112014017618A2 (enExample)
BR112014017627A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014017671A2 (enExample)